<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04358393</url>
  </required_header>
  <id_info>
    <org_study_id>APG115AU101</org_study_id>
    <nct_id>NCT04358393</nct_id>
  </id_info>
  <brief_title>A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS</brief_title>
  <official_title>A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients With Relapse/Refractory AML, CMML or MDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascentage Pharma Group Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascentage Pharma Group Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two Part study in patients with relapsed/refractory acute myeloid leukemia (AML),&#xD;
      chronic myelomonocytic leukemia (CMML), or high risk myelodysplastic syndrome (MDS) that will&#xD;
      initially evaluate the safety and tolerability of APG-115 as a single agent in Part 1,&#xD;
      followed by a combination of APG-115 + 5-azacitidine (5-AZA) in Part 2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: Dose escalation of APG-115 will use standard 3+3 design. APG-115 is administered&#xD;
      orally once daily (QD) on Day 1-5 every 28-day cycle. The starting target dose is 100 mg&#xD;
      (dose level; DL1) and will be increased in subsequent cohorts to 150 mg (DL2), 200 mg (DL3),&#xD;
      and 250 mg (DL4), accordingly.&#xD;
&#xD;
      Part 2: Dose escalation of APG-115 in combination with 5-AZA will use standard 3+3 design.&#xD;
      5-AZA is administered at 75 mg/m˄2/d subcutaneously daily on Day 1-7 every 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>28 days</time_frame>
    <description>Part I is to assess the safety and tolerability of APG-115 by assessing the dose-limiting toxicity (DLT) of APG-115. End points include: Incidence of DLTs during the first 3 weeks of treatment of each dose cohort; Severity and frequency of any adverse event(s) (AE) and serious adverse event(s) (SAE) based on NCI CTCAE 5.0</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>AML</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>CMML</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>High-risk Myelodysplastic Syndrome</condition>
  <condition>MDS</condition>
  <arm_group>
    <arm_group_label>APG-115 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy given in part 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APG-115 + 5-azacitidine combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy given in part 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APG-115</intervention_name>
    <description>APG-115 given once daily on day 1-5 of every 28 day cycle</description>
    <arm_group_label>APG-115 + 5-azacitidine combination</arm_group_label>
    <arm_group_label>APG-115 monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-azacitidine</intervention_name>
    <description>5-AZA is given at 75 mg/m˄2/d subcutaneously daily on Day 1-7 every 28 days</description>
    <arm_group_label>APG-115 + 5-azacitidine combination</arm_group_label>
    <other_name>Vidaza</other_name>
    <other_name>Azadine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with a diagnosis of histologically confirmed relapsed or refractory AML,&#xD;
             CMML, or high-risk MDS (overall revised international prognostic scoring system&#xD;
             (IPSS-R) score &gt; 3, including intermediate, high, or very high risk) by World Health&#xD;
             Organization (WHO) classification for which no available standard therapies are&#xD;
             indicated or anticipated to result in a durable response.&#xD;
&#xD;
          2. Adequate organ function as defined below:&#xD;
&#xD;
               1. Liver function (total bilirubin &lt; or = 1.5 x upper limit of normal (ULN),&#xD;
                  aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &lt;3 x ULN&#xD;
&#xD;
               2. Kidney function (defined as a calculated creatinine clearance ≥ 60 mL/min;&#xD;
                  determined via urine collection for 24-hour creatinine clearance or by the&#xD;
                  Cockcroft Gault formula)&#xD;
&#xD;
               3. Known cardiac ejection fraction of &gt; or = 45% within the past 3 months&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2&#xD;
&#xD;
          4. A negative serum pregnancy test is required within 1 week for all women of&#xD;
             childbearing potential prior to enrolling on this trial.&#xD;
&#xD;
          5. Patient must have the ability to understand the requirements of the study and signed&#xD;
             informed consent. A signed informed consent by the patient or legally authorized&#xD;
             representative is required prior to their enrollment on the protocol.&#xD;
&#xD;
          6. Subject must have a projected life expectancy of at least 12 weeks.&#xD;
&#xD;
          7. Subject has a white blood cell count &lt; 25 × 10˄9/L. Note: Hydroxyurea is permitted to&#xD;
             meet this criteria.&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          1. Pregnant women are excluded.&#xD;
&#xD;
          2. Uncontrolled intercurrent illness including, but not limited to active uncontrolled&#xD;
             infection, symptomatic congestive heart failure (NYHA Class III or IV), unstable&#xD;
             angina pectoris, clinically significant cardiac arrhythmia, or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements.&#xD;
&#xD;
          3. Have had leukemia therapy for 14 days prior to starting investigational drug. However,&#xD;
             patients with rapidly proliferative disease may receive hydroxyurea as needed until 24&#xD;
             hours prior to starting therapy on this protocol and during the first cycle of study.&#xD;
&#xD;
          4. Have acute promyelocytic leukemia.&#xD;
&#xD;
          5. Active infection requiring systemic antibiotic/antifungal medication, known clinically&#xD;
             active hepatitis B or C, or HIV infection.&#xD;
&#xD;
          6. Have received allogeneic hematopoietic stem cell transplant (HSCT) within 12 months&#xD;
             prior to the first dose, or who have active/ongoing graft-versus host disease (GVHD),&#xD;
             or require continued treatment with systemic immunosuppressive agents (calcineurin&#xD;
             inhibitors within 4 weeks prior to the first dose), or received autologous&#xD;
             hematopoietic stem cell transplantation within 6 months prior to the first dose.&#xD;
&#xD;
          7. Documented hypersensitivity to any of the components of the therapy program&#xD;
&#xD;
          8. Active, uncontrolled central nervous system (CNS) leukemia will not be eligible.&#xD;
&#xD;
          9. Men and women of childbearing potential who do not practice contraception. Women of&#xD;
             childbearing potential and men must agree to use at least 1 form of barrier birth&#xD;
             control (such as condom) prior to study entry and for the duration of study&#xD;
             participation.&#xD;
&#xD;
         10. Any prior systemic MDM2-p53 inhibitor treatment&#xD;
&#xD;
         11. Any other condition or circumstance that would, in the opinion of the investigator,&#xD;
             make the patient unsuitable for participation in the study.&#xD;
&#xD;
         12. History of other malignancies within 2 years prior to study entry, with the exception&#xD;
             of:&#xD;
&#xD;
               1. Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of&#xD;
                  breast&#xD;
&#xD;
               2. Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin&#xD;
&#xD;
               3. Previous malignancy confined and surgically resected (or treated with other&#xD;
                  modalities) with curative intention: requires discussion with sponsor&#xD;
&#xD;
         13. Failure to have recovered (Grade &gt; 1) from prior treatment (including chemotherapy,&#xD;
             targeted therapy, immunotherapy, experimental agents, radiation, or surgery)&#xD;
&#xD;
         14. Significant screening electrocardiogram (ECG) abnormalities including left bundle&#xD;
             branch block, 2nd degree atrioventricular (AV) block type II, 3rd degree block, or&#xD;
             corrected QT interval (QTc) ≥470 msec&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yifan Zhai, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ascentage Pharma Group Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathryn Shantz</last_name>
    <phone>301-802-3414</phone>
    <email>kate.shantz@ascentage.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Minahan</last_name>
      <phone>480-256-5463</phone>
      <email>Kevin.Minahan@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Matthew Ulrickson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Gibson</last_name>
      <email>Patricia.Gibson@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Kathryn Wilson</last_name>
      <email>Kathryn.Wilson@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher Benton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Unviersity</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Daly</last_name>
      <phone>919-660-2077</phone>
      <email>christine.daly@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Harry Erba, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catinna Mallett</last_name>
      <email>catinna.mallett@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Jonathan Huntzinger</last_name>
      <email>Jonathan.huntzinger@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Moshe Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tapan Kadia, MD</last_name>
      <phone>713-563-3534</phone>
      <email>tkadia@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Tapan Kadia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penny Watkins</last_name>
      <email>Penny.Watkins@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Habte Yimer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frances Gatlin</last_name>
      <email>Frances.Gatlin@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Hackmaster</last_name>
      <email>melissa.hackmaster@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mitul Gandhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 21, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TP53</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

